Teva signs $1.5b. funding deal with banking syndicate

January 24, 2011 15:13


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceutical Industries Ltd. on Monday signed a new three-year, $1.5 billion unsecured revolving credit line with a banking syndicate. The new credit line replaces and expands existing credit lines at terms that are more favorable to Teva.

Teva CFO Eyal Desheh said, “Our ability to negotiate better terms today is proof of the strength of our cash flow and balance sheet. This facility is part of our financial strategy to secure liquidity for future business needs through revolving credit lines. We were pleased to see strong desire from all our relationship banks to commit to this facility."

Related Content

Breaking news
July 16, 2018
Trump and Putin to hold first summit talks as twitchy West looks on